Results 161 to 170 of about 25,833,379 (292)

Comparison of outcomes after DA‐EPOCH‐R or GMALL high‐intensity therapy for front‐line treatment of Burkitt lymphoma: A retrospective cohort

British Journal of Haematology, EarlyView.
In this retrospective cohort of adult Burkitt lymphoma, DA‐EPOCH‐R showed no signal of inferior survival or relapse risk compared with GMALL‐based high‐intensity therapy. Outcomes were driven mainly by established prognostic factors, particularly age, advanced stage and Burkitt lymphoma International Prognostic Index.
Eduard Schulz, Florian Posch, Kristina Friedrich, Peter Neumeister, Katharina T. Prochazka   +4 more
wiley   +1 more source

Central nervous system lymphoma and neurolymphomatosis in equids

Background Lymphoma affecting the central and peripheral nervous systems in equids is rarely reported. Hypothesis/Objectives To describe the clinical ...
Kelly O’Connell, Maria I Calero, Kevin D Woolard, Monica Aleman, William Vernau, Emily Berryhill   +5 more
core   +1 more source

BrECADD in three days: Implementation of a condensed intensive first‐line regimen in Hodgkin lymphoma

British Journal of Haematology, EarlyView.
BrECADD can be delivered over 3 days instead of four, reducing intravenous treatment days by 25% without compromising dose intensity. Among 30 patients with advanced‐stage Hodgkin lymphoma, no unexpected toxicity was observed; there were no early discontinuations, and 1‐year progression‐free and overall survival were both 100%.
Christian Peter Jaworek, Maja Supprian, Paul Jan Bröckelmann, Hishan Tharmaseelan, Justin Ferdinandus, Dennis A. Eichenauer, Anne Sophie Robertz, Janina Jablonski, Vincent Combüchen, Jan‐Oliver Staak, Karin Töpelt, Jan‐Michel Heger, Jon Rischewski, Jannik Stemler, Wolfram Klapper, Peter Borchmann, Bastian von Tresckow   +16 more
wiley   +1 more source

SAKK 35/14 randomized trial of rituximab with or without ibrutinib for patients with untreated follicular lymphoma

British Journal of Haematology, EarlyView.
Summary The randomized phase II SAKK 35/14 trial, conducted by the Swiss Group for Clinical Cancer Research (SAKK) and the Nordic Lymphoma Group (NLG), compared efficacy and safety of rituximab (375 mg/m2 intravenously for 4 weeks followed by maintenance every 2 months for 24 months) plus placebo (arm A) versus the same schedule of rituximab plus ...
Maria Cristina Pirosa, Marianne Brodtkorb, Sämi Schär, Björn E. Wahlin, Micaela Hernberg, Michael Pedersen, Anastasios Stathis, Thilo Zander, Urban Novak, Thorsten Zenz, Natalie Fischer, Fatime Krasniqi, Felicitas Hitz, Ann‐Sofie Johansson, David Löfgren, Peter Albert Meyer, Anne Turid Bjørnevik, Giulio Sartori, Stefanie Hayoz, Andrea Fuhrer, Luzia Steiner, Francesco Bertoni, Luca Ceriani, Stefan Dirnhofer, Emanuele Zucca, Bjørn Østenstad   +25 more
wiley   +1 more source

Case Report: Primary Central Nervous System Lymphoma With "Wine Glass" Sign Presenting as Somnolence and Fatigue. [PDF]

Am J Case Rep
Xu R, Chen X.
europepmc   +1 more source

Primary central nervous system lymphoma-current standards and recent developments. [PDF]

Neurooncol Pract
Van Der Meulen M, Vermaat JSP, Galldiks N, Issa S, De Bresser J, Doorduijn JK, Bromberg JEC.   +6 more
europepmc   +1 more source

Primary Central Nervous System Lymphoma Masquerading as Multiple Sclerosis - A Case Report

Primary central nervous system lymphoma represents a rare and aggressive variant of non-Hodgkin lymphoma that remains confined to the central nervous system without systemic involvement at the time of diagnosis.[1] We present a case of a 48-year-old ...
Naval Kishore Bajaj, Syed Areeb Yazdani, Sunidhi Kumari S., Nagarjuna Chary   +3 more
core   +1 more source

Dynamic risk stratification using early CAR‐T expansion in R/R LBCL treated with axicabtagene ciloleucel

British Journal of Haematology, EarlyView.
Higher chimeric antigen receptor‐T expansion at day 7 is associated with improved progression‐free survival but also increased toxicity in axi‐cel treated patients with R/R large B‐cell lymphoma, independent of other baseline patient and disease characteristics.
Brydon Panozzo, Samuel Robinson, Adrian G. Minson, Jian Li, Kylie Baldwin, Hamish W. Scott, Jane Oliaro, Aaron J. N. Wong, Samantha van der Linde, Nicole L. O'Leary, Philip A. Thompson, John F. Seymour, Mary Ann Anderson, Constantine S. Tam, Simon J. Harrison, Michael J. Dickinson, David A. Westerman, Mark R. Dowling   +17 more
wiley   +1 more source

Primary dural lymphoma: a rare subtype of primary central nervous system lymphoma (PCNSL)

Arquivos de Neuro-Psiquiatria, 2011
Fabiano Reis, Ricardo Schwingel, Luciano de Souza Queiroz, Verônica de Araújo Zanardi   +3 more
doaj   +1 more source

Third ventricle non-Hodgkin lymphoma: An unusual presentation of primary central nervous system lymphoma. [PDF]

BMC Neurol
Uthayasuriyan N, Gowthaman SR, Pachiyappan JS, Damodaran AC, Ali MNH.   +4 more
europepmc   +1 more source